Hyperprolactinemia: pathophysiology and therapeutic approach.
Capozzi A, Scambia G, Pontecorvi A, Lello S.
Gynecol Endocrinol. 2015 Jul;31(7):506-10. doi: 10.3109/09513590.2015.1017810. Epub 2015 Jul 6.
The Prevalence of Menstrual Cycle Disorders in Female Athletes from Different Sports Disciplines: A Rapid Review.
Gimunová M, Paulínyová A, Bernaciková M, Paludo AC.
Int J Environ Res Public Health. 2022 Oct 31;19(21):14243. doi: 10.3390/ijerph192114243.
Hyperprolactinemia.
Majumdar A, Mangal NS.
J Hum Reprod Sci. 2013 Jul;6(3):168-75. doi: 10.4103/0974-1208.121400.
Diagnostic and therapeutic use of oral micronized progesterone in endocrinology.
Memi E, Pavli P, Papagianni M, Vrachnis N, Mastorakos G.
Rev Endocr Metab Disord. 2024 Aug;25(4):751-772. doi: 10.1007/s11154-024-09882-0. Epub 2024 Apr 23.
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C.
Cochrane Database Syst Rev. 2018 May 24;5(5):CD010287. doi: 10.1002/14651858.CD010287.pub3.
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C.
Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4.
Oligomenorrhea and secondary amenorrhea in the adolescent.
Wentz AC.
Med Clin North Am. 1975 Nov;59(6):1385-94. doi: 10.1016/s0025-7125(16)31938-1.
Combined Lifestyle and Herbal Medicine in Overweight Women with Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial.
Arentz S, Smith CA, Abbott J, Fahey P, Cheema BS, Bensoussan A.
Phytother Res. 2017 Sep;31(9):1330-1340. doi: 10.1002/ptr.5858. Epub 2017 Jul 7.
Menstrual disorders during adolescence.
Deligeoroglou E, Tsimaris P, Deliveliotou A, Christopoulos P, Creatsas G.
Pediatr Endocrinol Rev. 2006 Jan;3 Suppl 1:150-9.
The female athlete.
Warren MP, Shantha S.
Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):37-53. doi: 10.1053/beem.2000.0052.
